PHOENIX (March 23, 2020) – Medical toxicologists and emergency physicians are warning the public against the use of inappropriate medications and household products to prevent or treat COVID-19. In particular, Banner Health experts emphasize that chloroquine, a malaria medication, should not be ingested to treat or prevent this virus.Continue reading
Category Archives: AZBio News
Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia
Genentech will also provide 10,000 vials of Actemra to the U.S. Strategic National Stockpile
Current U.S. supply of Actemra for approved indications is not expected to be impactedContinue reading
COVID-19 Testing: What you need to know about getting tested
Arizonans seeking a test for COVID-19 are encouraged to visit the Arizona Department of Health Services website to find a location nearest them.
azhealth.gov/covid19testing
Federal Reserve announces extensive new measures to support the economy
March 23, 2020 – 8 AM EDT: The Federal Reserve is committed to using its full range of tools to support households, businesses, and the U.S. economy overall in this challenging time. The coronavirus pandemic is causing tremendous hardship across the United States and around the world. Our nation’s first priority is to care for those afflicted and to limit the further spread of the virus. While great uncertainty remains, it has become clear that our economy will face severe disruptions. Aggressive efforts must be taken across the public and private sectors to limit the losses to jobs and incomes and to promote a swift recovery once the disruptions abate.Continue reading
COVID-19 Update shared by an Arizona Emergency Physician and Legislator
Amish Shah, MD is an emergency physician at Dignity Health and a member of the Arizona House of Representative elected by the people of LD24 – Central Phoenix and South Scottsdale. On Saturday, March 20, 2020, Dr. Shah shared the message below via Facebook. This Facebook post is republished with permission from Dr. Shah. .Continue reading
First Rapid, Point-of-Care and Near-Patient Molecular Test for Detection of Virus that Causes COVID-19
Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test. The test has been designed to operate on any of Cepheid’s more than 23,000 automated GeneXpert® Systems worldwide, with a detection time of approximately 45 minutes.
SBA Offers Small Business COVID-19 Emergency Disaster Loans
The U.S. Small Business Administration is offering low-interest federal disaster loans for working capital to Arizona small businesses suffering substantial economic injury as a result of the Coronavirus. Loans are available for for profit and nonprofit businesses.Continue reading
BIO Launches Coronavirus Hub to Facilitate Exchange of Supplies & Services
The new Coronavirus Hub connects those companies that have relevant supplies, capacities, and resources to share, with those companies, researchers, or healthcare providers that need them. The new hub will enable users to post requests for urgently needed items, as well as to post the availability of supplies and capacityContinue reading
Funding Opportunities: National Institute on Aging at NIH
The National Institute on Aging at NIH (NIA) posted six new Funding Opportunity Announcements in February. Check out what’s new.Continue reading
C-Path Receives FDA Grant to Establish Rare Disease Clinical Outcome Assessment Consortium
TUCSON, Ariz., March 19, 2020 — The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has funded a cooperative agreement to establish a Rare Disease Clinical Outcome Assessment (COA) Consortium. The grant (U01FD006882)* was awarded to the Critical Path Institute (C-Path) with the National Organization for Rare Disorders (NORD) as a sub-awardee. The first step taken toward the establishment of the new consortium has been the creation of the Rare Disease Subcommittee within C-Path’s Patient-Reported Outcome (PRO) Consortium. The PRO Consortium will serve as an incubator for the maturation of a pre-competitive, multi-stakeholder consortium within C-Path’s COA Program.Continue reading